Luye Pharma Group Limited (HKG: 2186) announced a strategic cooperation agreement with Sinopharm Group Co., Ltd. to drive channel distribution, market access, and resource synergy across multiple Luye Pharma products. The partnership designates Mimeixin (Oxycodone and Naloxone Prolonged‑release Tablets) as the flagship collaboration asset, leveraging Sinopharm’s national distribution network to expand reach for China’s first oral naloxone‑containing analgesic following its 2025 NRDL inclusion.
Partnership Framework
Element
Detail
Parties
Luye Pharma Group (HKG: 2186) + Sinopharm Group Co., Ltd.
Agreement Type
Strategic cooperation (channel distribution focus)
China’s first oral naloxone‑containing analgesic; only innovative combination providing potent analgesia + mechanistic OIC resolution
Reimbursement Status
NRDL included (2025) – national reimbursement coverage secured
Strategic Rationale & Market Impact
Factor
Implication
Distribution Scale
Sinopharm’s 30,000+ hospital network and tier‑1/2/3 city coverage accelerates Mimeixin penetration vs. Luye standalone commercialization
NRDL Leverage
2025 reimbursement listing enables rapid volume ramp with Sinopharm’s government hospital relationships
Competitive Moat
First‑mover advantage in OIC‑addressing opioid segment vs. pure oxycodone generics (OxyContin) and tapentadol
Pain Market Size
China severe pain market estimated RMB 12‑15 billion; opioid analgesics ~40% share with growing demand for tolerability‑enhanced formulations
Clinical Value Proposition: Addresses unmet need in cancer pain and post‑surgical settings where OIC drives non‑adherence; naloxone component differentiates from standard oxycodone CR
Revenue Forecast: Mimeixin projected to reach RMB 300‑500 million annual sales by 2028 with Sinopharm distribution scale‑up
National hospital/pharmacy logistics, cold‑chain capability
Market Access
NRDL negotiation expertise
Government procurement relationships, provincial bidding support
Medical Education
KOL engagement, pain specialist outreach
Primary care physician network, continuing medical education platforms
Forward‑Looking Statements This brief contains forward‑looking statements regarding partnership execution, volume projections, and market penetration for Mimeixin. Actual results may differ due to narcotic analgesic regulatory controls, regional reimbursement variation, and competitive pricing pressure from generic oxycodone formulations.-Fineline Info & Tech
By Fineline Cube 